MOVEMENT DISORDERS ASSOCIATED WITH ARIPIPRAZOLE USE: A CASE SERIES

被引:23
作者
Hall, Deborah A. [1 ]
Agarwal, Pinky [2 ]
Griffith, Alida [2 ]
Segro, Vicki [3 ]
Seeberger, Lauren C. [4 ]
机构
[1] Rush Univ, Chicago, IL 60612 USA
[2] Booth Gardner Parkinsons Care Ctr Kirkland, Washington, DC USA
[3] Colorado Neurol Inst, Denver, CO USA
[4] Movement Disorders Ctr Elks Boise, Boise, ID USA
关键词
Akathesia; aripiprazole; drug-induced; dyskinesia; dystonia; parkinsonism; tardive; NEUROLEPTIC MALIGNANT SYNDROME; PARKINSONS-DISEASE; ACUTE DYSTONIA; SAFETY; PSYCHOSIS; EFFICACY; PLACEBO;
D O I
10.3109/00207450903225553
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Aripiprazole is an atypical antipsychotic that is a partial agonist at the D2 and 5HT1a receptors and an antagonist at 5HT2a receptors. Despite previous hypotheses that it would be less likely to cause movement disorders, recent reports suggest it actually may be more likely to cause movement disorders than other atypical antipsychotics. This case series illustrates the variety of movement disorders associated with aripiprazole use at three movement disorder clinics. It also suggests that aripiprazole be used with caution in patients with a prior history of dystonia, parkinsonism, or previous tardive dyskinesia.
引用
收藏
页码:2274 / 2279
页数:6
相关论文
共 15 条
  • [1] Aripiprazole and neuroleptic malignant syndrome
    Chakraborty, N
    Johnston, T
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2004, 19 (06) : 351 - 353
  • [2] Aripiprazole-induced acute dystonia
    Desarkar, P
    Thakur, A
    Sinha, VK
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2006, 163 (06) : 1112 - 1113
  • [3] Aripiprazole for drug-induced psychosis in Parkinson disease: Preliminary experience
    Fernandez, HH
    Trieschmann, ME
    Friedman, JH
    [J]. CLINICAL NEUROPHARMACOLOGY, 2004, 27 (01) : 4 - 5
  • [4] Acute dystonia with low-dosage aripiprazole in Tourette's disorder
    Fountoulakis, KN
    Siamouli, M
    Kantartzis, S
    Panagiotidis, P
    Lacovides, A
    St Kaprinis, G
    [J]. ANNALS OF PHARMACOTHERAPY, 2006, 40 (04) : 775 - 777
  • [5] Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease
    Friedman, Joseph H.
    Berman, Robert M.
    Goetz, Christopher G.
    Factor, Stewart A.
    Ondo, William G.
    Wojcieszek, Joanne
    Carson, William H.
    Marcus, Ronald N.
    [J]. MOVEMENT DISORDERS, 2006, 21 (12) : 2078 - 2081
  • [6] Extrapyramidal adverse events associated with atypical antipsychotic treatment of bipolar disorder
    Gentile, Salvatore
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2007, 27 (01) : 35 - 45
  • [7] Gupta Sanjay, 2004, Ann Clin Psychiatry, V16, P155, DOI 10.1080/10401230490487007
  • [8] Neuroleptic malignant syndrome and aripiprazole
    Hammerman, S
    Lam, C
    Caroff, SN
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2006, 45 (06) : 639 - 641
  • [9] The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor
    Jordan, S
    Koprivica, V
    Chen, RY
    Tottori, K
    Kikuchi, T
    Altar, CA
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 441 (03) : 137 - 140
  • [10] Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder
    Kane, JM
    Carson, WH
    Saha, AR
    McQuade, RD
    Ingenito, GG
    Zimbroff, DL
    Ali, MW
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (09) : 763 - 771